Appetite Suppression

Most pivotal GLP-1 / dual / triple agonist trials run 26 to 104 weeks. Real-world use — particularly for obesity indication — is increasingly multi-year. The safety signal for extended chronic use beyond two years is under-characterised, particularly for rare serious adverse events (acute kidney injury, cholelithiasis, pancreatitis) that require large real-world populations to detect.

Implications: Current approval is based on medium-term outcome data. Users planning multi-year therapy are extrapolating beyond the trial base. Resolution: prospective registry-scale follow-up over 5–10 years, particularly for tirzepatide and retatrutide where the multi-pathway profile expands the surface area for long-term effects.

Lean-mass loss is acknowledged as a risk (15–40% of total weight lost). Long-term bone density changes are barely studied. Whether sustained muscle loss at these proportions translates to clinically meaningful frailty, sarcopenia, or fracture risk at 5-year and 10-year horizons is unknown.

Implications: In elderly and frail patients, this is the risk most likely to drive net harm despite successful weight loss. Resolution: longitudinal DEXA studies paired with functional outcome measurement (grip strength, falls, fractures) in older populations on chronic therapy.

Animal studies show skeletal and visceral malformations. Human data is inadequate to evaluate congenital disability risk or effects on mother / infant. The class is broadly contraindicated — but the evidence base is absent, not reassuring.

Implications: Unplanned pregnancy during therapy is a real clinical scenario given the oral-contraceptive interaction. Without human data, counselling is defensive by default. Resolution: pregnancy exposure registries to accumulate observational data on unplanned in-utero exposure.

'Caution required' is the current guidance in severe organ impairment — without detailed dose-adjustment protocols for most compounds. The combination of GI-driven volume contraction risk and reduced clearance is clinically important but under-quantified.

Implications: Clinicians managing patients with chronic kidney disease or hepatic dysfunction are operating on extrapolation rather than guidance. Resolution: targeted PK studies in mild, moderate, and severe impairment for the major compounds.

Most comparisons between GLP-1 / dual / triple agonists rely on literature-based meta-analyses rather than direct head-to-head trials. Decisions about semaglutide vs tirzepatide vs retatrutide are typically made on indirect cross-study comparisons with different populations, different follow-up periods, and different endpoints.

Implications: 'Tirzepatide vs semaglutide' choices at the prescriber level are reasoned inferences, not settled evidence. Resolution: direct head-to-head RCTs with matched populations and common endpoints, which are commercially unattractive but clinically necessary.

Biological rationale for combining GLP-1 therapy with omega-3s, zinc, specific probiotics, and other nutritional adjuncts is frequently discussed. Direct clinical trial evidence testing these specific combinations as adjuncts to peptide therapy is largely absent.

Implications: Nutritional adjunct recommendations during GLP-1 therapy are currently mechanism-based, not outcomes-based. Some will turn out to be clinically meaningful; others will turn out to be placebo. Resolution: targeted factorial-design trials of peptide + specific adjunct vs peptide alone.

Dose stretching (10–14 day intervals), dose tapering (stepping down to 2.5–5 mg floor), and microdosing maintenance strategies are emerging in clinical practice. Large-scale trial data validating any of these as effective weight-maintenance strategies is not yet available.

Implications: Patients who want off high-dose therapy are navigating this without evidence-based guidance. Resolution: RCT comparing several maintenance strategies post-achievement of target weight — standard continuous dose vs tapered vs stretched vs discontinuation.

Theoretical combinations like retatrutide + cagrilintide lack any clinical trial data. CagriSema (cagrilintide + semaglutide) has emerging trial data; combinations further up the pathway stack are speculative. Grey-market stacking without this evidence is already occurring.

Implications: Users combining molecules are running uncontrolled n-of-1 experiments with unknown interaction profiles. Resolution: factorial-design trials of cross-class combinations at defined doses; until these exist, combination therapy outside CagriSema is not evidence-based.

Mood changes, depression / anxiety signals, and the 'food anhedonia' phenomenon are mentioned in safety discussions but rarely studied in depth. The degree to which appetite suppression spreads into broader reward-pathway flattening, and how this intersects with pre-existing psychiatric history, is under-characterised.

Implications: Patients with complex psychiatric history are navigating this without prospective guidance. Resolution: qualitative and quantitative studies specifically targeting reward-pathway effects and psychiatric outcomes in diverse populations.

Brain-region-specific peptide (BRP) produces ~50% appetite suppression in animal models without GI side effects — a striking mechanistic profile. Whether that translates to human efficacy at anywhere near that magnitude, and whether the clean GI profile holds, is entirely unknown at time of writing.

Implications: BRP is the most interesting 'if it works' candidate in the frontier class. Resolution: Phase 1 human trials with appetite and GI-tolerability endpoints. Until those exist, BRP is pre-clinical and should not be discussed as a clinical option.